What is Levalbuterol (Xopenex) used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Levalbuterol (Xopenex) is used for the treatment of asthma exacerbations and as a bronchodilator.

Key Points

  • Levalbuterol is the R-enantiomer of albuterol and has a similar effectiveness and side effect profile, but is more expensive 1.
  • The standard dose for levalbuterol is 0.075 mg/kg (minimum dose 1.25 mg) every 20 minutes for 3 doses, then 0.075-0.15 mg/kg up to 5 mg every 1-4 hours as needed 1.
  • Levalbuterol can be administered via nebulizer or metered-dose inhaler (MDI), with the MDI dose being equivalent to albuterol 1.
  • Levalbuterol is equivalent to 1.25 mg of racemic albuterol for efficacy and side effects, with 0.63 mg of levalbuterol being equivalent to 1.25 mg of racemic albuterol 1.
  • The use of levalbuterol has not been shown to have a significant advantage over albuterol in terms of efficacy or safety 1.

Administration and Dosage

  • Nebulizer solution: 0.075 mg/kg (minimum dose 1.25 mg) every 20 minutes for 3 doses, then 0.075-0.15 mg/kg up to 5 mg every 1-4 hours as needed 1.
  • MDI: 4-8 puffs every 20 minutes for 3 doses, then every 1-4 hours as needed 1.

Important Considerations

  • Levalbuterol should only be used as needed for acute asthma symptoms, and not as a preventative measure 1.
  • The use of levalbuterol in severe asthma exacerbations has not been extensively studied, and its effectiveness in this setting is unclear 1.

From the FDA Drug Label

INDICATIONS AND USAGE: Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

  • Levalbuterol (Xopenex) is used for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease.
  • The approved age range for use is 6 years of age and older, including adults and adolescents 2.

From the Research

Uses of Levalbuterol (Xopenex)

  • Levalbuterol, also known as Xopenex, is used to treat patients with asthma and chronic obstructive lung disease (COPD) 3, 4, 5, 6, 7
  • It is a single-isomer formulation of the beta2-adrenergic agonist albuterol, which provides greater bronchodilation than racemic albuterol 3, 5
  • Levalbuterol is used as a quick-relief bronchodilator medication to control intermittent symptoms of cough, wheeze, and bronchoconstriction, as well as acute exacerbations 3
  • It is also used in the maintenance and treatment of associated symptoms of COPD, including shortness of breath 3

Comparison with Racemic Albuterol

  • Levalbuterol has been shown to provide comparable bronchodilation to racemic albuterol at lower doses, with the potential for reduced beta-mediated adverse effects in adults and children 3, 5
  • Some studies have suggested that levalbuterol may be more effective than racemic albuterol in patients with moderate to severe asthma, especially with racemic albuterol overuse 4
  • However, other studies have found that clinical outcomes are similar between levalbuterol and albuterol, with some differences in treatment costs and hospital length of stay 6, 7

Clinical Outcomes and Treatment Costs

  • Studies have compared the clinical outcomes and treatment costs of levalbuterol versus albuterol in hospitalized adults with COPD or asthma, with mixed results 6, 7
  • One study found that levalbuterol was associated with a length-of-stay savings of 0.91 days, a total cost savings of $556, and a decrease in the likelihood of hospital readmission of 67% 6
  • Another study found that mean total treatment costs per patient were significantly greater with the use of levalbuterol, and hospital length of stay was significantly greater in the levalbuterol group 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.

The Journal of the American Osteopathic Association, 2004

Research

Levalbuterol versus albuterol.

Current allergy and asthma reports, 2009

Research

Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003

Research

Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.